Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naive and Experienced Patients
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naive and Experienced Patients
复制标题
DOI：
10.2169/internalmedicine.9341-17
复制
发表时间：
2018-01-01
影响因子：
1.2
通讯作者：
Ueki, Yukitaka
中科院分区：
文献类型：
--
作者：
Mori, Shunsuke;Yoshitama, Tamami;Ueki, Yukitaka
目的本研究旨在直接比较托法替尼治疗甲氨蝶呤难治性类风湿关节炎（RA）的生物制剂初治患者和生物制剂反应不足患者的结局。方法前瞻性纳入并随访了113例具有高或中度临床疾病活动指数（CDAI）的患者（36例生物制剂初治患者和77例生物制剂治疗患者）。患者接受5 mg托法替布每日两次治疗。结果治疗6个月后，65例患者（57.5%）达到CDAI 50，即改善≥ 50%。CDAI 50无应答者既往使用生物制剂的数量是应答者的两倍（2.2 vs 1.1，p
Objective This study was designed to directly compare the outcomes of tofacitinib therapy for methotrexate-refractory rheumatoid arthritis (RA) between biologic-naive patients and patients who had experienced an inadequate response to biological agents.Methods We prospectively enrolled and followed 113 patients who had a high or moderate clinical disease activity index (CDAI) (36 biologic-naive patients and 77 biologic-experienced patients). Patients received 5 mg of tofacitinib twice daily. Effectiveness and adverse events were examined at month 6 of treatment.Results At month 6, 65 patients (57.5%) reached CDAI50, which is defined as achieving >= 50% improvement. The number of previous biological agents was twice as high in CDAI50 non-responders as in responders (2.2 versus 1.1, p